New discovery to aid in diagnosis and treatment of kidney disease

Jul 01, 2009

Researchers from Boston University School of Medicine (BUSM) in collaboration with scientists at the University of Louisville and the University of Nice Sophia Antipolis in France, have identified the target antigen PLA2R in patients with idiopathic membranous nephropathy (kidney disease), which has implications for the diagnosis and treatment of this disease. These findings appear in the July 2 issue of the New England Journal of Medicine.

Idiopathic membranous nephropathy involves the thickening and dysfunction of the filtering parts of the kidneys called glomeruli. It is caused when antibodies attack the glomeruli causing large amounts of protein to leak into the urine. It is a relatively common cause of adult-onset kidney disease that can progress over time to cause . Until now, the diagnosis of membranous nephropathy required a kidney biopsy as there are no blood or urine tests to specifically distinguish membranous nephropathy from other causes of . This is because up until now the protein that is the target of the circulating auto-antibodies has never been identified.

To identify the target antigen in patients with this condition, the researchers used circulating antibodies from adults with this disease to detect normal glomerular proteins. Subsequent analysis with the use of mass spectrometry and confirmation with the use of protein-specific reagents allowed for identification and characterization of the predominant protein detected by these circulating antibodies.

According to the researchers this discovery has important implications for both the diagnosis and treatment of membranous nephropathy. "Identifying the antigen will enable development of a simple blood test that could replace the need for a kidney biopsy and establish which patients are most likely to benefit from immunosuppressive treatment," said senior author David Salant, MD, a professor of medicine at BUSM and chief of the renal section at Boston Medical Center.

"Our findings show that PLA2R is a major target antigen in idiopathic membranous nephropathy. Seventy percent of our patients with biopsy-proven idiopathic membranous nephropathy had IgG antibodies that reacted with PLA2R, a constituent of normal human glomeruli," he added.

Source: Boston University Medical Center

Explore further: High hopes rest on 800 vials of experimental Ebola vaccine shipped from Canada

add to favorites email to friend print save as pdf

Related Stories

Uric acid may provide early clues to diabetic kidney disease

Mar 18, 2008

For patients with type 1 diabetes, increased levels of uric acid in the blood may be an early sign of diabetic kidney disease—appearing before any significant change in urine albumin level, the standard screening test, ...

Discovery could lead to much-needed kidney failure treatment

Mar 12, 2008

The unwanted activation of an important cell-signaling pathway may play a role in two kidney problems that are major causes of end-stage renal disease, scientists at the Albert Einstein College of Medicine of Yeshiva University ...

Recommended for you

Poll: Many doubt hospitals can handle Ebola

1 hour ago

A new poll finds most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient.

Number of Ebola cases nears 10,000

1 hour ago

The number of people with Ebola is set to hit 10,000 in West Africa, the World Health Organization said, as the scramble to find a cure gathered pace.

'Breath test' shows promise for diagnosing fungal pneumonia

2 hours ago

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the ...

Where Ebola battles are won

11 hours ago

(HealthDay)—Four hospitals that are home to advanced biocontainment facilities have become America's ground zero in the treatment of Ebola patients.

User comments : 0